Somatic mutations in certain tyrosine kinases have emerged as central 'drivers' of specific
cancers and these mutant proteins are proving to be excellent substrates for targeted …

The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung
cancer and the subsequent discovery of activating EGFR mutations have led to an explosion …

Despite tremendous progress in the last decade, lung adenocarcinoma still represents a
tumor with unfavorable prognosis when detected at advanced clinical stage. High-stage …

Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …

Somatic mutations within the kinase domain of the epidermal growth factor receptor (EGFR)
are present in approximately10% of non-small-cell lung cancer (NSCLC), with an increased …

Simple Summary Epidermal growth factor receptor (EGFR) mutations occur in a significant
number of lung cancer patients. Treatment outcomes in this subset of patients has greatly …

Considerable knowledge has accumulated about mutations of the epidermal growth factor
receptor (EGFR)-tyrosine kinase domain since these were first identified in 2004. Patients …

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

The most frequent epidermal growth factor receptor (EGFR) mutations found by traditional or
comprehensive molecular profiling of lung adenocarcinomas include indels of exon 19 (the …

Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-
small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine …